东江集团控股(02283) - 2025 - 中期业绩

Company Information and Announcements Company Profile TK Group (Holdings) Limited, stock code 2283, announced its interim results for the six months ended June 30, 2025 - Company Name: TK Group (Holdings) Limited - Stock Code: 2283[2] - Announcement Content: Interim results for the six months ended June 30, 2025[2][3] Financial Performance Summary Key Financial Indicators For the six months ended June 30, 2025, revenue increased by 4.3% to HKD 1,050,255 thousand, profit for the period rose 8.8% to HKD 86,774 thousand, basic earnings per share increased to HKD 10.5 cents, and both gross and net margins improved 2025 H1 Key Financial Indicators Comparison (HKD thousands) | Indicator | 2025 (HKD thousands) | 2024 (HKD thousands) | Change (%) | | :--- | :--- | :--- | :--- | | Revenue | 1,050,255 | 1,007,209 | 4.3% | | Profit for the period | 86,774 | 79,742 | 8.8% | | Basic EPS (HK cents) | 10.5 | 9.6 | 9.4% | | Proposed Interim Dividend (HK cents) | 4.3 | 4.0 | 7.5% | | Gross Margin | 25.3% | 24.8% | +0.5pp | | Net Margin | 8.3% | 7.9% | +0.4pp | | Return on Equity | 5.2% | 5.1% | +0.1pp | | Return on Assets | 3.4% | 3.2% | +0.2pp | | Inventory Turnover Days | 106 | 104 | +2 days | | Trade Receivables Turnover Days | 72 | 66 | +6 days | | Trade Payables Turnover Days | 72 | 71 | +1 day | Financial Position As of June 30, 2025, net current assets slightly decreased, but the current ratio remained high at 262.6% with no bank borrowings, indicating a robust financial structure 2025 June 30 Financial Position Comparison (HKD thousands) | Indicator | 2025 June 30 (HKD thousands) | 2024 Dec 31 (HKD thousands) | Change (%) | | :--- | :--- | :--- | :--- | | Net Current Assets | 1,249,384 | 1,264,692 | -1.2% | | Current Ratio | 262.6% | 263.4% | -0.8pp | | Quick Ratio | 201.6% | 209.2% | -7.6pp | | Gearing Ratio | Not Applicable | Not Applicable | - | | Bank Borrowings | None | None | - | Interim Condensed Consolidated Financial Statements Interim Condensed Consolidated Statement of Comprehensive Income In H1 2025, revenue grew 4.3% and gross profit 6.1%, but operating profit decreased 10.9% due to non-recurring items; profit for the period increased 8.8%, and total comprehensive income significantly rose to HKD 126,789 thousand, mainly from foreign currency translation differences 2025 H1 Consolidated Statement of Comprehensive Income Key Data (HKD thousands) | Indicator | 2025 (HKD thousands) | 2024 (HKD thousands) | Change (%) | | :--- | :--- | :--- | :--- | | Revenue | 1,050,255 | 1,007,209 | 4.3% | | Cost of Sales | (784,872) | (757,191) | 3.7% | | Gross Profit | 265,383 | 250,018 | 6.1% | | Operating Profit | 90,969 | 102,045 | -10.9% | | Profit Before Income Tax | 101,360 | 111,439 | -9.0% | | Income Tax Expense | (14,586) | (31,697) | -54.0% | | Profit for the Period | 86,774 | 79,742 | 8.8% | | Total Comprehensive Income for the Period | 126,789 | 32,694 | 287.8% | | Basic and Diluted EPS (HK cents) | 10.5 | 9.6 | 9.4% | Interim Condensed Consolidated Statement of Financial Position As of June 30, 2025, total assets, non-current assets, and current assets slightly decreased, while total equity and total liabilities also saw minor reductions, maintaining a stable financial structure with no bank borrowings 2025 June 30 Consolidated Statement of Financial Position Key Data (HKD thousands) | Indicator | 2025 June 30 (HKD thousands) | 2024 Dec 31 (HKD thousands) | Change (%) | | :--- | :--- | :--- | :--- | | Assets | | | | | Non-current Assets | 519,273 | 538,074 | -3.5% | | Current Assets | 2,017,732 | 2,038,669 | -1.0% | | Total Assets | 2,537,005 | 2,576,743 | -1.5% | | Equity | | | | | Total Equity | 1,682,585 | 1,711,287 | -1.7% | | Liabilities | | | | | Non-current Liabilities | 86,072 | 91,479 | -5.9% | | Current Liabilities | 768,348 | 773,977 | -0.7% | | Total Liabilities | 854,420 | 865,456 | -1.3% | | Total Equity and Liabilities | 2,537,005 | 2,576,743 | -1.5% | Notes to the Interim Financial Information General Information The company, registered in the Cayman Islands, primarily manufactures, sells, and modifies moulds and injection moulding components in China, with shares listed on the HKEX since 2013 - Company registered in the Cayman Islands, primarily engaged in the manufacturing, sale, subcontracting, production, and modification of moulds and injection moulding components in China[9] - Listed on the Hong Kong Stock Exchange on December 20, 2013[10] - Financial information presented in HKD and approved for publication by the Board on August 18, 2025, unaudited but reviewed by the Audit Committee[11][12][13] Basis of Preparation and Accounting Policies The interim financial information is prepared in accordance with HKAS 34 and consistent with the 2024 annual financial statements, with no significant impact from new or revised standards adopted this period - Basis of Preparation: Prepared in accordance with Hong Kong Accounting Standard 34 "Interim Financial Reporting" issued by the Hong Kong Institute of Certified Public Accountants[14] - Accounting Policies: Consistent with the previous financial year, with no significant impact on financial performance or position from new and revised standards adopted during the period[15][16] Segment Information In H1 2025, mould manufacturing revenue grew strongly by 30.4% to HKD 350,548 thousand, while plastic injection moulding components manufacturing revenue decreased by 5.2% to HKD 699,707 thousand 2025 H1 Segment Revenue and Results (HKD thousands) | Segment | 2025 Revenue (HKD thousands) | 2024 Revenue (HKD thousands) | Revenue Change (%) | 2025 Results (HKD thousands) | 2024 Results (HKD thousands) | | :--- | :--- | :--- | :--- | :--- | :--- | | Mould Manufacturing | 350,548 | 268,912 | 30.4% | 115,385 | 90,055 | | Plastic Injection Moulding Components Manufacturing | 699,707 | 738,297 | -5.2% | 149,998 | 159,963 | | Total (External Customers) | 1,050,255 | 1,007,209 | 4.3% | 265,383 | 250,018 | Income Tax Expense Income tax expense significantly decreased by 54.0% to HKD 14,586 thousand in H1 2025, with the effective tax rate falling to 14.4%, primarily due to reduced withholding income tax 2025 H1 Income Tax Expense (HKD thousands) | Tax Type | 2025 (HKD thousands) | 2024 (HKD thousands) | Change (%) | | :--- | :--- | :--- | :--- | | Current Income Tax | 11,169 | 16,398 | -31.9% | | Deferred Income Tax | 3,417 | 15,299 | -77.7% | | Total Income Tax Expense | 14,586 | 31,697 | -54.0% | | Effective Tax Rate | 14.4% | 28.4% | -14.0pp | - China corporate income tax rate is 25%, with some high-tech enterprises enjoying a 15% preferential tax rate; withholding income tax is typically 10%, with a 5% preferential rate for Hong Kong tax residents[21] Earnings Per Share Basic earnings per share for H1 2025 increased by 9.4% to HKD 10.5 cents, with diluted earnings per share being substantially the same due to minimal dilutive potential shares 2025 H1 Earnings Per Share Calculation | Indicator | 2025 | 2024 | | :--- | :--- | :--- | | Profit for the period (HKD thousands) | 86,774 | 79,742 | | Weighted Average Number of Ordinary Shares (thousands of shares) | 829,149 | 827,529 | | Basic EPS (HK cents) | 10.5 | 9.6 | | Diluted EPS | Substantially the same | Substantially the same | Trade and Other Receivables As of June 30, 2025, total trade and other receivables increased to HKD 481,677 thousand, with net trade receivables at HKD 421,241 thousand, mostly within three months 2025 June 30 Trade and Other Receivables (HKD thousands) | Item | 2025 June 30 (HKD thousands) | 2024 Dec 31 (HKD thousands) | | :--- | :--- | :--- | | Net Trade Receivables | 421,241 | 399,686 | | Prepayments and Deposits | 23,383 | 26,740 | | Recoverable VAT | 13,887 | 14,226 | | Advances to Employees | 4,562 | 4,364 | | Loans to Associates | 1,193 | 808 | | Export Tax Refund Receivables | 3,115 | 1,281 | | Others | 14,296 | 7,161 | | Total | 481,677 | 454,266 | Trade Receivables Ageing Analysis (HKD thousands) | Ageing | 2025 June 30 (HKD thousands) | 2024 Dec 31 (HKD thousands) | | :--- | :--- | :--- | | Within 3 months | 376,509 | 358,739 | | Over 3 months but within 1 year | 54,005 | 48,030 | | Over 1 year | 2,231 | 2,643 | | Total | 432,745 | 409,412 | - No new loans were provided to associates during the period[27] Trade and Other Payables As of June 30, 2025, total trade and other payables increased to HKD 450,423 thousand, with trade payables at HKD 333,371 thousand, mostly due within 90 days 2025 June 30 Trade and Other Payables (HKD thousands) | Item | 2025 June 30 (HKD thousands) | 2024 Dec 31 (HKD thousands) | | :--- | :--- | :--- | | Trade Payables | 333,371 | 292,330 | | Accrued Wages and Employee Benefits | 85,844 | 117,135 | | Accrued Expenses and Other Payables | 16,818 | 14,071 | | Other Tax Payables | 14,390 | 12,368 | | Total | 450,423 | 435,904 | Trade Payables Ageing Analysis (HKD thousands) | Ageing | 2025 June 30 (HKD thousands) | 2024 Dec 31 (HKD thousands) | | :--- | :--- | :--- | | Within 90 days | 260,207 | 214,374 | | 91 to 120 days | 52,306 | 47,414 | | 121 to 365 days | 12,894 | 22,236 | | Over 365 days | 7,964 | 8,306 | | Total | 333,371 | 292,330 | Share Capital and Share Premium As of June 30, 2025, the company's authorized and issued share capital remained unchanged at 2,000,000 thousand shares and 833,260 thousand shares respectively, with share premium also stable at HKD 251,293 thousand Share Capital and Share Premium (HKD thousands) | Item | Number of Ordinary Shares (thousands of shares) | Par Value (HKD thousands) | Share Premium (HKD thousands) | Total (HKD thousands) | | :--- | :--- | :--- | :--- | :--- | | Authorized Share Capital | 2,000,000 | 200,000 | - | - | | Issued and Fully Paid Share Capital | 833,260 | 83,326 | 251,293 | 334,619 | Dividends The Board resolved to declare an interim dividend of HKD 4.3 cents per share for H1 2025, an increase from the prior year, with 2024 final and special dividends already paid in June 2025 - On August 18, 2025, the Board resolved to declare an interim dividend of HKD 4.3 cents per share (2024 interim: HKD 4.0 cents), totaling approximately HKD 35,830,000[31] - The 2024 final dividend (HKD 8.8 cents per share) and special dividend (HKD 10.0 cents per share) were paid on June 12, 2025[31] Management Discussion and Analysis Business Review In H1 2025, despite global economic challenges, the company's total revenue grew 4.3%, driven by a strong 30.4% increase in mould manufacturing, offsetting a 5.2% decline in plastic injection moulding components manufacturing - Global economic environment faces challenges, with slowing US economic growth and weak consumer spending; the Eurozone shows a moderate recovery; China's GDP grew 5.3%, demonstrating resilience[32] 2025 H1 Revenue by Business Segment Comparison (HKD millions) | Business Segment | 2025 H1 (HKD millions) | 2024 H1 (HKD millions) | Change (%) | | :--- | :--- | :--- | :--- | | Mould Manufacturing | 350.6 | 268.9 | 30.4% | | Plastic Injection Moulding Components Manufacturing | 699.7 | 738.3 | -5.2% | | Total Revenue | 1,050.3 | 1,007.2 | 4.3% | Revenue by Downstream Industry Analysis In H1 2025, revenue from automotive, medical & personal care, and other industries grew significantly, with automotive up 30.3%, while mobile & wearables, smart home, e-vaporizers, and commercial communication equipment saw declines, with the latter down 45.4% 2025 H1 Revenue by Downstream Industry Analysis (HKD millions) | Industry | 2025 (HKD millions) | 2025 (%) | 2024 (HKD millions) | 2024 (%) | Change (HKD millions) | Change (%) | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Mobile & Wearables | 313.7 | 29.9 | 326.2 | 32.4 | -12.5 | -3.8 | | Automotive | 187.3 | 17.8 | 143.7 | 14.3 | 43.6 | 30.3 | | Medical & Personal Care | 163.6 | 15.6 | 142.5 | 14.1 | 21.1 | 14.8 | | Smart Home | 99.2 | 9.4 | 99.9 | 9.9 | -0.7 | -0.7 | | E-vaporizers | 77.5 | 7.4 | 95.5 | 9.5 | -18.0 | -18.8 | | Commercial Communication Equipment | 49.1 | 4.7 | 90.0 | 8.9 | -40.9 | -45.4 | | Others | 159.9 | 15.2 | 109.4 | 10.9 | 50.5 | 46.2 | | Total | 1,050.3 | 100.0 | 1,007.2 | 100.0 | 43.1 | 4.3 | Overall Financial Highlights In H1 2025, gross profit increased 6.1% to HKD 265.4 million, gross margin improved by 0.5 percentage points to 25.3%, profit attributable to owners rose 8.8% to HKD 86.8 million, basic EPS increased to HKD 10.5 cents, and sales orders on hand grew 12.4% 2025 H1 Overall Financial Highlights (HKD millions) | Indicator | 2025 H1 (HKD millions) | 2024 H1 (HKD millions) | Change (%) | | :--- | :--- | :--- | :--- | | Gross Profit | 265.4 | 250.0 | 6.1% | | Gross Margin | 25.3% | 24.8% | +0.5pp | | Profit Attributable to Owners | 86.8 | 79.7 | 8.8% | | Net Margin | 8.3% | 7.9% | +0.4pp | | Basic EPS (HK cents) | 10.5 | 9.6 | 9.4% | | Net Cash | 1,067.2 | 1,060.5 | 0.6% | | Sales Orders on Hand | 999.3 | 889.1 (2024 Dec 31) | 12.4% | Business Segment Analysis Mould manufacturing revenue surged 30.4% due to automotive recovery and market demand, though gross margin slightly decreased due to investment in precision moulds; plastic injection moulding components revenue fell 5.2% due to a slowdown in consumer markets, but medical & personal care performed strongly Mould Manufacturing Business Mould manufacturing revenue grew 30.4% to HKD 350.6 million, driven by automotive parts demand and market expansion, but gross margin slightly decreased to 32.9% due to increased investment in precision mould manufacturing capabilities - Mould manufacturing business revenue: HKD 350.6 million, a 30.4% year-on-year increase, accounting for 33.4% of total revenue[36] - Business Focus: Super-large standard moulds primarily for automotive parts, while precision moulds cover high-end consumer electronics such as mobile phones, wearables, smart home devices, and medical & personal care products[36] - Strategy: Increased investment to enhance precision mould manufacturing capabilities and refinement, actively expanding into medical, consumer electronics, and smart home markets to diversify client base[37] - Gross Margin: 32.9%, a 0.6 percentage point year-on-year decrease, mainly due to increased investment in precision mould manufacturing capabilities[37][41] Plastic Injection Moulding Components Manufacturing Business Plastic injection moulding components revenue decreased 5.2% to HKD 699.7 million due to weak consumer confidence, though medical & personal care showed strong growth, while e-vaporizers declined due to regulatory tightening, resulting in a slight gross margin drop to 21.4% - Plastic injection moulding components manufacturing business revenue: HKD 699.7 million, a 5.2% year-on-year decrease, accounting for 66.6% of total revenue[38] - Key Impact: Weak consumer confidence in Europe and America led to shrinking product demand, with some brand clients adjusting orders or delaying shipments[38] Plastic Injection Business Key Downstream Industry Revenue Changes | Industry | Revenue Change (%) | | :--- | :--- | | Mobile & Wearables | -3.8% | | Smart Home | -0.7% | | Commercial Communication Equipment | -45.4% | | Medical & Personal Care | +14.8% (Medical Consumables +24.0%, Personal Care +4.5%) | | E-vaporizers | -18.8% | - Strategy: Continuously strengthening efforts to expand overseas and domestic medical brand clients, seizing development opportunities in the medical and health industry[39] - Gross Margin: 21.4%, a slight 0.3 percentage point year-on-year decrease, mainly due to the slowdown in the consumer market affecting order volumes[39][41] Analysis of Statement of Profit or Loss Items This section details the changes and drivers for revenue, gross profit, other income, selling expenses, administrative expenses, finance income, share of results of associates, operating profit, income tax expense, and profit for the period in H1 2025 Revenue H1 2025 revenue increased 4.3% to HKD 1,050.3 million, primarily driven by a 30.4% growth in mould manufacturing, offsetting a 5.2% decline in plastic injection moulding components manufacturing - Total Revenue: HKD 1,050.3 million, a 4.3% year-on-year increase[40] - Driving Factors: Mould manufacturing business grew 30.4%, while plastic injection moulding components manufacturing business decreased 5.2%[40] Gross Profit Gross profit increased 6.1% to HKD 265.4 million, with gross margin rising 0.5 percentage points to 25.3%, mainly due to the growth of higher-margin mould manufacturing business - Gross Profit: HKD 265.4 million, a 6.1% year-on-year increase; Gross Margin: 25.3%, up 0.5 percentage points[41] - Mould Manufacturing Segment Gross Margin: 32.9%, down 0.6 percentage points, due to increased investment in precision mould manufacturing capabilities[41] - Plastic Injection Moulding Components Manufacturing Segment Gross Margin: 21.4%, down 0.3 percentage points, due to the slowdown in the consumer market affecting order volumes[41] Other Income Other income decreased by 34.4% to HKD 12.8 million, primarily due to a reduction in government grants - Other Income: HKD 12.8 million, a 34.4% year-on-year decrease, mainly due to reduced government grants[42] Other (Losses)/Gains – Net Other net losses amounted to HKD 0.2 million this period, a shift from a HKD 5.9 million gain in the prior year, mainly due to reduced exchange gains - Other (Losses)/Gains – Net: A loss of HKD 0.2 million this period, compared to a gain of HKD 5.9 million in the prior year, primarily due to reduced exchange gains[43] Selling Expenses Selling expenses decreased by 28.3% to HKD 24.6 million, representing 2.3% of total revenue, primarily due to lower transportation costs - Selling Expenses: HKD 24.6 million, a 28.3% year-on-year decrease, representing 2.3% of total revenue, mainly due to reduced transportation costs[44] Administrative Expenses Administrative expenses increased by 18.8% to HKD 160.9 million, representing 15.3% of total revenue, mainly due to higher R&D staff costs and consulting fees for organizational diagnosis and strategic enhancement - Administrative Expenses: HKD 160.9 million, an 18.8% year-on-year increase, representing 15.3% of total revenue[45] - Driving Factors: 1) Increased employee expenses for R&D personnel; 2) Increased consulting service fees for organizational diagnosis and strategic enhancement[45] Finance Income – Net Net finance income increased by 12.9% to HKD 9.5 million, primarily driven by higher interest income - Net Finance Income: HKD 9.5 million, a 12.9% year-on-year increase, primarily due to higher interest income[46] Share of Results of Associates Share of profit from associates decreased by 9.0% to HKD 0.9 million - Share of Profit from Associates: HKD 0.9 million, a 9.0% year-on-year decrease[47] Operating Profit Operating profit decreased by 10.9% to HKD 91.0 million, primarily impacted by non-recurring items, while core operating profit (excluding non-recurring items) increased by 8.8% to HKD 95.6 million - Operating Profit: HKD 91.0 million, a 10.9% year-on-year decrease, primarily impacted by non-recurring items[48] - Core Operating Profit (excluding non-recurring items): HKD 95.6 million, an 8.8% year-on-year increase[48] Income Tax Expense Income tax expense significantly decreased by 54.0% to HKD 14.6 million, with the effective tax rate falling to 14.4%, mainly due to reduced withholding income tax - Income Tax Expense: HKD 14.6 million, a 54.0% year-on-year decrease; Effective Tax Rate: 14.4%, a 14.0 percentage point year-on-year decrease, mainly due to reduced withholding income tax[49] Profit for the Period Profit for the period increased by 8.8% to HKD 86.8 million - Profit for the Period: HKD 86.8 million, an 8.8% year-on-year increase[50] Seasonality Company sales are seasonal, with higher demand in the second half of the year driven by holiday seasons and new product launches, accounting for 57% of 2024 revenue - Sales are subject to seasonality, with demand typically higher in the second half of the year, driven by seasonal consumption patterns (e.g., Thanksgiving, Christmas holidays) and new product launches[51] - 2024 Revenue Distribution: 43% in H1, 57% in H2[51] Liquidity, Financial Resources and Ratios As of June 30, 2025, net current assets slightly decreased, but cash and bank balances remained high, and the current ratio was robust, with no bank borrowings and an inapplicable gearing ratio Liquidity Position As of June 30, 2025, net current assets were HKD 1,249.4 million, cash and bank balances were HKD 1,067.2 million, the current ratio was 262.6%, total equity was HKD 1,682.6 million, and there were no bank borrowings 2025 June 30 Liquidity Position (HKD millions) | Indicator | 2025 June 30 (HKD millions) | 2024 Dec 31 (HKD millions) | Change (%) | | :--- | :--- | :--- | :--- | | Net Current Assets | 1,249.4 | 1,264.7 | -1.2% | | Cash and Bank Balances | 1,067.2 | 1,164.8 | -8.4% | | Current Ratio | 262.6% | 263.4% | -0.8pp | | Total Equity | 1,682.6 | 1,711.3 | -1.7% | | Bank Borrowings | None | None | - | | Gearing Ratio | Not Applicable | Not Applicable | - | Maturity Profile of Borrowings As of June 30, 2025, the Group had no bank borrowings - The Group had no bank borrowings as of June 30, 2025, and December 31, 2024[53] Liquidity Ratios Inventory turnover days slightly increased by 2 days to 106 days, trade receivables turnover days increased by 6 days to 72 days due to domestic business expansion, and trade payables turnover days slightly increased by 1 day to 72 days, while the current ratio slightly decreased by 0.8 percentage points to 262.6% 2025 H1 Liquidity Ratios | Indicator | 2025 | 2024 | Change | | :--- | :--- | :--- | :--- | | Inventory Turnover Days | 106 | 104 | +2 days | | Trade Receivables Turnover Days | 72 | 66 | +6 days | | Trade Payables Turnover Days | 72 | 71 | +1 day | | Current Ratio | 262.6% | 263.4% | -0.8pp | - The increase in trade receivables turnover days is mainly due to the expansion of domestic business, where domestic sales customers enjoy longer credit terms[56] Pledged Assets As of June 30, 2025, the Group had no pledged assets - The Group had no pledged assets as of June 30, 2025, and December 31, 2024[59] Risk Management and Capital Structure The company prudently manages foreign exchange risk through natural hedging and close monitoring of exchange rate fluctuations, maintaining an unchanged capital structure primarily composed of ordinary shares and other reserves Foreign Exchange Risk Management The company primarily faces foreign exchange risks from USD, EUR, and RMB, managed prudently through CEO-approved policies, CFO-executed daily management, and natural hedging, with regular policy reviews - Primary foreign exchange risks: USD, EUR, and RMB[60] - Management Strategy: Policies approved by the CEO, daily management executed by the CFO, primarily using prudent measures such as natural hedging, with regular evaluations and reviews[60] RMB Exchange Rate Risk The company's revenue is primarily denominated in USD, EUR, RMB, and HKD, while expenses are mainly in RMB, with no RMB hedging agreements currently in place - Revenue is primarily denominated in USD, EUR, RMB, and HKD, while expenses are mainly in RMB[61] - No RMB hedging agreements have been entered into[61] Capital Structure The company's capital structure remained unchanged during the period, consisting mainly of ordinary shares and other reserves - The capital structure remained unchanged during the period, comprising ordinary shares and other reserves[62] Material Capital Investment Plans The company plans to invest in capacity expansion and projects as outlined in the prospectus to capture future business growth, primarily funded by internal resources - Plans to invest in capacity expansion and investment projects to capture future business growth[63] - Future funding sources will primarily be internal resources[63] Employees and Remuneration Policies As of June 30, 2025, the company had 3,861 full-time employees and 292 dispatched workers, offering competitive remuneration, a share award scheme, training, and mandatory social security contributions for Chinese employees Employee Count Comparison | Employee Type | 2025 June 30 | 2024 Dec 31 | | :--- | :--- | :--- | | Full-time Employees | 3,861 | 3,687 | | Dispatched Workers | 292 | 114 | - Remuneration Policy: Offers competitive remuneration packages, a share award scheme, and training and development programs[64] - Benefits for Chinese Employees: Contributes to mandatory social security funds (pension, medical, unemployment, work injury, maternity insurance, and housing provident fund)[64] Material Acquisitions and Disposals For the six months ended June 30, 2025, the Group had no material acquisitions or disposals of subsidiaries - No material acquisitions or disposals of subsidiaries occurred during the period[65] Contingent Liabilities As of June 30, 2025, the Group had no material contingent liabilities - The Group had no material contingent liabilities as of June 30, 2025, and December 31, 2024[66] Outlook For the second half, global economic uncertainty persists, but China's economy is expected to remain stable; the company will pursue technological innovation, deepen TactoTek collaboration for IMSE® technology, target AI-driven consumer electronics, enhance global supply chain resilience with a "China + Vietnam" strategy, and implement strategic upgrades with BCG to drive innovation and consolidate market leadership - Macroeconomic Outlook: High global economic uncertainty, with the World Bank lowering 2025 global GDP growth forecast to 2.3%; China's economy is expected to continue its stable and improving trend, with GDP growth forecast maintained at 4.5%, and policy stimuli expected to boost H2 consumer demand[67] - Technological Innovation: Strategic cooperation with Finland's TactoTek, obtaining IMSE® technology patent license, becoming the first local Chinese automotive-grade IMSE® electrical functional film supplier, with IMSE® production lines deployed, shortening product development cycles by over 50%[68] - Market Opportunities: AI large model technology drives innovation in smart terminal industries, with consumer electronics (mobile phones, AR, AIPC, smart home) becoming key for AI implementation; the company has entered the supply chain of a metaverse industry leader, supporting AR glasses R&D[69] - Supply Chain Layout: Completed "China + Vietnam" dual production base deployment, with Vietnam factory expanded by 5,000 square meters to enhance global supply chain resilience; domestic production bases (Suzhou, Shenzhen Guangming District) upgraded, expanding capacity, and strengthening medical consumables cleanrooms and mould manufacturing technology[70] - Strategic Upgrade: Engaged Boston Consulting Group (BCG) for an organizational diagnosis and strategic upgrade project to identify improvement areas and formulate solutions[71] - Future Development: Responding to the national "new quality productive forces" strategy, optimizing production management with data middle platform, AI, and Industry 4.0 technologies to improve efficiency and reduce costs; maintaining rigorous financial management to consolidate leading strengths in innovative technology and high-end manufacturing[72] Other Information Purchase, Sale or Redemption of the Company’s Listed Securities For the six months ended June 30, 2025, neither the company nor its subsidiaries purchased, sold, or redeemed any of the company's listed securities - Neither the company nor its subsidiaries purchased, sold, or redeemed any listed securities during the period[73] Post Balance Sheet Events No material post balance sheet events affecting the Group occurred from June 30, 2025, up to the date of this announcement - No material post balance sheet events occurred from the end of the reporting period until the announcement date[74] Corporate Governance Code The Board is committed to maintaining and promoting investor confidence and sustainable development, has established appropriate corporate governance policies, and believes it complied with all code provisions in Appendix C1 of the HKEX Listing Rules for the six months ended June 30, 2025 - The company is committed to strengthening corporate governance measures to ensure transparency and accountability[75] - The Board believes it complied with all code provisions of the Corporate Governance Code set out in Appendix C1 of the HKEX Listing Rules during the period[76] Audit Committee The Audit Committee, comprising three independent non-executive directors, has reviewed the Group's accounting policies, risk management, internal controls, and financial reporting matters, including this interim financial information - The Audit Committee, composed of three independent non-executive directors, has reviewed accounting policies, risk management, internal controls, and financial reporting matters, including this interim financial information[77] Declaration and Payment of Dividends The Board resolved on August 18, 2025, to declare an interim dividend of HKD 4.3 cents per share for the six months ended June 30, 2025, totaling HKD 35,830,180, payable on September 17, 2025 - The Board resolved to declare an interim dividend of HKD 4.3 cents per share, totaling HKD 35,830,180[78] - The interim dividend is expected to be paid on September 17, 2025, to shareholders whose names appear on the register of members on August 29, 2025[78] Closure of Register of Members To determine eligibility for the interim dividend, the company will suspend share transfer registration from August 28 to August 29, 2025; unregistered shareholders must register by 4:30 p.m. on August 27, 2025 - Share transfer registration suspension dates: August 28 to August 29, 2025 (both days inclusive)[79] - Deadline for registration to qualify for the dividend: 4:30 p.m. on August 27, 2025[79] Publication of Interim Results Announcement and Interim Report The interim results announcement has been published on the HKEX and company websites, and the interim report will be dispatched to shareholders and published on the same websites in due course - The interim results announcement has been published on the HKEX website (www.hkexnews.hk) and the company's website (www.tkmold.com)[80](index=80&type=chunk) - The interim report will be dispatched to shareholders and published on the aforementioned websites in due course[81]